Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

Dan G. Duda, Christopher G. Willett, Marek Ancukiewicz, Emmanuelle di Tomaso, Mira Shah, Brian G. Czito, Rex Bentley, Martin Poleski, Gregory Y. Lauwers, Madeline Carroll, Douglas Tyler, Christopher Mantyh, Paul Shellito, Jeffrey W. Clark, Rakesh K. Jain

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002-2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with "vascular normalization"-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting.

Original languageEnglish (US)
Pages (from-to)577-583
Number of pages7
JournalOncologist
Volume15
Issue number6
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor-1
Rectal Neoplasms
Biomarkers
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor
Intercellular Signaling Peptides and Proteins
Fluorouracil
Blood Vessels
Radiotherapy
Urine
Bevacizumab
Therapeutics
Neoplasms

Keywords

  • Bevacizumab
  • Biomarker
  • Chemoradiation
  • Rectal cancer
  • sVEGFR-1
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. / Duda, Dan G.; Willett, Christopher G.; Ancukiewicz, Marek; di Tomaso, Emmanuelle; Shah, Mira; Czito, Brian G.; Bentley, Rex; Poleski, Martin; Lauwers, Gregory Y.; Carroll, Madeline; Tyler, Douglas; Mantyh, Christopher; Shellito, Paul; Clark, Jeffrey W.; Jain, Rakesh K.

In: Oncologist, Vol. 15, No. 6, 2010, p. 577-583.

Research output: Contribution to journalArticle

Duda, DG, Willett, CG, Ancukiewicz, M, di Tomaso, E, Shah, M, Czito, BG, Bentley, R, Poleski, M, Lauwers, GY, Carroll, M, Tyler, D, Mantyh, C, Shellito, P, Clark, JW & Jain, RK 2010, 'Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer', Oncologist, vol. 15, no. 6, pp. 577-583. https://doi.org/10.1634/theoncologist.2010-0029
Duda, Dan G. ; Willett, Christopher G. ; Ancukiewicz, Marek ; di Tomaso, Emmanuelle ; Shah, Mira ; Czito, Brian G. ; Bentley, Rex ; Poleski, Martin ; Lauwers, Gregory Y. ; Carroll, Madeline ; Tyler, Douglas ; Mantyh, Christopher ; Shellito, Paul ; Clark, Jeffrey W. ; Jain, Rakesh K. / Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. In: Oncologist. 2010 ; Vol. 15, No. 6. pp. 577-583.
@article{cd253ecc02b44fd69a4a6ddd2b0bad31,
title = "Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer",
abstract = "We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002-2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with {"}vascular normalization{"}-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting.",
keywords = "Bevacizumab, Biomarker, Chemoradiation, Rectal cancer, sVEGFR-1, Toxicity",
author = "Duda, {Dan G.} and Willett, {Christopher G.} and Marek Ancukiewicz and {di Tomaso}, Emmanuelle and Mira Shah and Czito, {Brian G.} and Rex Bentley and Martin Poleski and Lauwers, {Gregory Y.} and Madeline Carroll and Douglas Tyler and Christopher Mantyh and Paul Shellito and Clark, {Jeffrey W.} and Jain, {Rakesh K.}",
year = "2010",
doi = "10.1634/theoncologist.2010-0029",
language = "English (US)",
volume = "15",
pages = "577--583",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

AU - Duda, Dan G.

AU - Willett, Christopher G.

AU - Ancukiewicz, Marek

AU - di Tomaso, Emmanuelle

AU - Shah, Mira

AU - Czito, Brian G.

AU - Bentley, Rex

AU - Poleski, Martin

AU - Lauwers, Gregory Y.

AU - Carroll, Madeline

AU - Tyler, Douglas

AU - Mantyh, Christopher

AU - Shellito, Paul

AU - Clark, Jeffrey W.

AU - Jain, Rakesh K.

PY - 2010

Y1 - 2010

N2 - We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002-2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with "vascular normalization"-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting.

AB - We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002-2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with "vascular normalization"-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting.

KW - Bevacizumab

KW - Biomarker

KW - Chemoradiation

KW - Rectal cancer

KW - sVEGFR-1

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=77954991606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954991606&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2010-0029

DO - 10.1634/theoncologist.2010-0029

M3 - Article

VL - 15

SP - 577

EP - 583

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 6

ER -